

Please type a plus sign (+) inside this box

PTO SB 08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	09/757,289
Filing Date	January 8, 2001
First Named Inventor	Shawn DeFrees et al.
Group Art Unit	1652
Examiner Name	Unassigned
Attorney Docket Number	019957-013821US

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
CJ	AA	5,705,367		Gotschlich	Jan. 6, 1998	
	AB	5,798,233		Gotschlich	Aug. 25, 1998	
	AC	5,541,083		Paulson et al.	Jul. 30, 1996	
	AD	5,922,577		DeFrees et al.	Jul. 13, 1999	
	AE	5,945,314		Prieto et al.	Aug. 31, 1999	
	AF	5,047,335		Paulson et al.	Sept. 10, 1991	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
CJ	AG	PCT	WO 98/44145		Prieto	Oct. 8, 1998		No
	AH	EPO	EP 0870841 A1		Koizumi	Oct. 14, 1998		No
	AI	EPO	EP 0861902 A1		Koizumi	Sep. 2, 1998		No

Examiner Signature

*Christopher Turner*

Date Considered

9/11/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231

SF 1304543 v1

Please type a plus sign (+) inside this box

PTO SB 08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OIA control number

Substitute for form 1449B-PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

## Complete if Known

Application Number 09/757,289  
Filing Date January 8, 2001  
First Named Inventor Shawn DeFrees et al.  
Group Art Unit 1652  
Examiner Name Unassigned  
Attorney Docket Number 019957-013821US

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
CTD	AJ	Endo et al., "Large-scale production of N-acetylglucosamine through bacterial coupling," <i>Carbohydrate Res.</i> 316:179-183 (1999).
	AK	Koizumi et al., "Large-scale production of UDP-galactose and globotriose by coupling metabolically engineered bacteria," <i>Nature Biotech.</i> 16:847-850 (1998).
	AL	Vimr and Troy, "Regulation of Sialic Acid Metabolism in <i>Escherichia coli</i> : Role of N-Acetylneuraminase Pyruvate-Lyase," <i>J. Bacteriol.</i> Vol. 164, No. 2, 854-860 (1985).
	AM	Mergaert et al., "The nodulation gene <i>nolK</i> of <i>Azorhizobium caulinodans</i> is involved in the formation of GDP-fucose from GDP-mannose," <i>FFBS Letters</i> 409:312-316 (1997).
	AN	Gonzales-Clemente et al., "High Production of polysialic Acid [Neu5Aca(2-8)-Neu5Aca(2-9)] <sub>n</sub> by <i>Escherichia coli</i> K92 Grown in a Chemically Defined Medium," <i>Biol. Chem. Hoppe-Seyler</i> , Vol. 371, pp. 1101-1106 (1990).
	AO	Cho and Troy II, "Polysialic acid engineering: Synthesis of polysialylated neoglycosphingolipids by using the polysialyltransferase from neuroinvasive <i>Escherichia coli</i> K1," <i>Proc. Natl. Acad. Sci. USA</i> 91:11427-11431 (1994).
	AP	Williams and Wimpenny, "Extracellular Polysaccharide Biosynthesis by <i>Pseudomonas</i> NCIB 11264. Studies on Precursor-forming Enzymes and Factors Affecting Exopolysaccharide Production by Washed Suspensions," <i>J. of Gen. Microbiol.</i> 116:133-141 (1980).
	AQ	Mengin-Lecreux et al., "Pool Levels of UDP N-Acetylglucosamine and UDP N-Acetylglucosamine-Enolpyruvate in <i>Escherichia coli</i> and Correlation with Peptidoglycan Synthesis," <i>J. of Bacteriology</i> , Vol. 154, No. 3, 1284-1290 (1983).
	AR	Lloret et al., "Genetic analysis of the transcriptional arrangement of <i>Azotobacter vinelandii</i> alginate biosynthetic genes: identification of two independent promoters," <i>Mol. Microbiol.</i> 21(3):449-457 (1996).
	AS	Lindahl et al., "Regulated Diversity of Heparan Sulfate," <i>J. Biol. Chem.</i> 273(39):24979-24982 (1998).
	AT	Zacharek et al., "Bacteria Targeted by Human Natural Antibodies Using $\alpha$ -Gal Conjugated Receptor-Specific Glycopolymers," <i>Bioorg. Med. Chem.</i> 7:1549-1558 (1999).

Examiner Signature

*Charles R. Ponder*

Date Considered

4/11/05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

\* Unique citation designation number \* Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1304543 v1

Please type a plus sign (+) inside this box

PTO SB-08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B:PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

## Complete if Known

Application Number	09/757,289
Filing Date	January 8, 2001
First Named Inventor	Shawn DeFrees et al.
Group Art Unit	1652
Examiner Name	Unassigned
Attorney Docket Number	019957-013821US

TECH CENTER 1600/2900

FEB 05 2002

RECEIVED

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CDD	AU	Wang et al., "Enhanced Inhibition of Human anti-Gal Antibody Binding to Mammalian Cells by Synthetic $\alpha$ -Gal Epitope Polymers., <i>J. Amer. Chem. Soc.</i> , 121(36):8174-8181 (1999).	
	AV	Kawaguchi et al., "An Improved Method for the Fermentative Production of GDP-mannose from 5'-GMP", <i>J. Ferment. Tech.</i> 49(3):195-201 (1971)	
	AW	Kawaguchi et al., "Studies on Microbial Metabolisms of Sugar Nucleotides, Part V., "Effects of Various Factors on the Fermentative Production of GDP-mannose, GDP and GTP from 5'-GMP by Air dried Cells of Baker's Yeast." <i>Agr. Biol. Chem</i> 34(6):908-918 (1970).	
	AX	Janczuk et al., "Alpha-Gal oligosaccharides: chemistry and potential biomedical application." <i>Curr. Med. Chem.</i> 6(2):155-64 (1999)	
	AY	Gilbert et al., "The synthesis of sialylated oligosaccharides using a CMP-Neu5Ac synthetase/sialyltransferase fusion." <i>Nat. Biotech.</i> 16:769-772 (1998).	

Examiner  
Signature

*Shawn DeFrees*

Date  
Considered

4/1/05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1304543 v1